Vitalant opens cell-based analytics lab to support allogeneic therapy developers
New Phoenix laboratory expands Vitalant’s CGT analytics network with additional donor characterization and immune profiling capabilities
8 Oct 2026
Vitalant has launched its analytics lab at the Phoenix Bioscience Core, expanding its cell and gene therapy (CGT) analytical capabilities for developers of allogeneic cell therapies.
The new laboratory will support cell-based analytics, providing enhanced characterization of allogeneic donors and immune profiling, and offering flexible support for assay development across cell-based analytics platforms.
This latest facility with specialized equipment is designed to serve biotech and pharmaceutical therapy developers and other teams seeking access to scientific expertise and broader donor datasets.
The analytics lab, which supports a wide range of immunomodulatory drug developers, is part of Vitalant's integrated clinical, production and testing network organized around centers of excellence, creating community access across Vitalant’s national footprint.
The lab supports the growth of Vitalant's characterized allogeneic donor base and nationwide collection infrastructure. By expanding characterization capabilities, Vitalant aims to help developers evaluate source material more effectively and, over time, explore data-driven approaches to therapy selection based on patient-cell characteristics.
The lab is anchored within the Phoenix Bioscience Core, a 30-acre life sciences innovation district in the heart of downtown Phoenix and part of Vitalant’s flagship presence in the city. This summer, Vitalant also unveiled new investigative and diagnostic analytical capabilities through its expanded coagulation laboratory in Pittsburgh.
“Our new analytics lab strengthens Vitalant’s clinical, technical and scientific capabilities and insights offered to allogeneic therapy developers,” said Becky Cap, senior vice president of biotherapies at Vitalant. “This coordinated ecosystem provides the critical infrastructure and services developers need to scale advanced therapies and bring innovative treatments to patients faster.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Tags
Frequently asked questions
Show frequently asked questions
What capabilities does Vitalant’s new analytics lab offer cell and gene therapy developers?
Vitalant’s analytics lab provides cell-based analytics, enhanced characterization of allogeneic donors, immune profiling and flexible assay development support across cell-based analytics platforms. These capabilities help developers evaluate source material and advance allogeneic cell therapies.
Where is Vitalant’s new cell and gene therapy analytics lab located?
The laboratory is located within the Phoenix Bioscience Core, a 30-acre life sciences innovation district in downtown Phoenix. It is part of Vitalant’s flagship presence in the city and its integrated national clinical, production and testing network.
How will Vitalant’s analytics lab support allogeneic therapy development?
The lab expands Vitalant’s characterized allogeneic donor base and nationwide collection infrastructure. Its scientific expertise, broader donor datasets and specialized equipment can help therapy developers scale advanced treatments, evaluate source material more effectively and explore data-driven therapy selection based on patient-cell characteristics.